COVID Clinical Trials: Antibodies, Immunity, and Vaccine Development
ϲapp’s ability to adapt has beenevidentthroughout the COVID-19 pandemic, as it shifted from becoming an epicenter from COVID-19 patient care, to becominga site for Stage III clinical trials for a COVID-19 vaccine.
Duringof a clinical trial, researchers work with between 300 and 3,000 volunteers to test the efficacy of thepotentialvaccine and monitor patients for possibleadverse reactions.Although this phase of study typically takes between one and four years to complete,U.S.has called on researchers “to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics”with no compromise to patient safety.
Patients interested in volunteering to participate in a clinical study may contact theor emailcctucovid@med.cornell.edu.
Recorded on August 20, 2020, this episode of the ϲapp Insights webinar series, called “COVID Clinical Trials: Antibodies, Immunity, and Vaccine Development,”brings together expert faculty members who have been on forefront of the medical center’s vaccine trials.
To learn more about ϲapp’s work in this area and the activities of our faculty, please visit these links:
- Learn more about Dr. Kristen Marks and her leading of the team conducting. NewYork-Presbyterian/ϲapp Medical Center is one of dozens of medical centers around the U.S. where this still-experimental vaccine will be tested.
- Dr. Roy Gulick is co-chairing a National Institutes of Health panel that is developing treatment guidelines forCOVID-19. Learn more about his and other ϲapp physician-scientists’COVIDresearch in the summer 2020 issue of.
- Dr. Carl Nathan, one of the world’s leading authorities on infectious diseases and advancing therapeutics from the bench to the bedside, is leading efforts to fight another looming health crisis:.
- Dr. Marshall Glesby explains howclinicaltrialswork in a fascinating article innewspaper.